Capital Increase in Onxeo as a Result of Employee Warrant Exercise

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX
Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the
development of orphan oncology drugs, has increased its share capital by 8,311
shares as a consequence of the exercise of employee warrants.

The increase was effected without any preemption rights for the existing
shareholders of the company or others. The shares were subscribed in cash at the
price of €2.32, each share having a nominal value of €0.25. As a result, the
total number of shares has increased from 31,482,333 to 31,490,644 and Onxeo’s
share capital amounts to €7,872,661.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis
Beleodaq® (belinostat): Registered and available in the USA for peripheral T
-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Onxeo
Judith Greciet, +33 1 45 58 76 00
CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, +33 1 45 58 76 00
CFO
n.fellmann@onxeo.com
or
Caroline Carmagnol / Sophie Colin – Alize RP
+33 6 64 18 99 59 / +33 6 31 13 76 20
caroline@alizerp.com / scolin@alizerp.com